NCT01933529 — ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)
ClinicalTrials.gov registry summary, not a standalone efficacy publication.
NCT01933529: UNKNOWN; 24 participants (estimated). The current registry status is UNKNOWN. ACTIVE_NOT_RECRUITING is only the last known status, not confirmation that the trial is still active. Enrollment is estimated, not actual. No registry results are posted. Do not automatically attach the separate painful-diabetic-neuropathy paper (PMID 25387363) to this prediabetes/drug-naive diabetes trial.
Registered clinical trial
Official ClinicalTrials.gov record.
- •Registry identifier: NCT01933529
- •Status: UNKNOWN
- •Phase: PHASE2
- •Conditions: Diabetes Type 2; Impaired Glucose Tolerance; Impaired Fasting Glucose
- •Enrollment: 24 (ESTIMATED)
- •Allocation: RANDOMIZED
- •Results posted: No
- •Registry last updated: 2015-09-03
- •Record checked: October 15, 2026
Interpretation and limitations
The current registry status is UNKNOWN. ACTIVE_NOT_RECRUITING is only the last known status, not confirmation that the trial is still active. Enrollment is estimated, not actual. No registry results are posted. Do not automatically attach the separate painful-diabetic-neuropathy paper (PMID 25387363) to this prediabetes/drug-naive diabetes trial.
Registration records describe trial plans and administrative status. Completion alone does not establish efficacy; missing results do not prove treatment failure. The Educational evidence badge distinguishes these records from peer-reviewed human outcome studies. This is a dated registry snapshot, not live monitoring.
Connected compound
ARA-290 / cibinetide monograph. Research education only, not treatment advice.
Keywords
For research use only. Not medical advice.